Guffanti M - Search Results

1

Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19.

Spagnuolo V, Guffanti M, Galli L, Poli A, Querini PR, Ripa M, Clementi M, Scarpellini P, Lazzarin A, Tresoldi M, Dagna L, Zangrillo A, Ciceri F, Castagna A; COVID-BioB study group. Spagnuolo V, et al. Among authors: guffanti m. Sci Rep. 2020 Dec 4;10(1):21291. doi: 10.1038/s41598-020-78039-1. Sci Rep. 2020. PMID: 33277573 Free PMC article.

2

Unusual presentation of cryptococcosis in a patient with AIDS.

Finazzi R, Guffanti M, Cernuschi M, Erembourg L, Capasso G, Ossi C, Gesu G. Finazzi R, et al. Among authors: guffanti m. Clin Infect Dis. 1996 Apr;22(4):709. doi: 10.1093/clinids/22.4.709. Clin Infect Dis. 1996. PMID: 8729210 No abstract available.

3

Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease.

Uberti-Foppa C, Lillo F, Terreni MR, Puglisi A, Guffanti M, Gianotti N, Lazzarin A. Uberti-Foppa C, et al. Among authors: guffanti m. Chest. 1998 Apr;113(4):919-23. doi: 10.1378/chest.113.4.919. Chest. 1998. PMID: 9554626

4

Recombinant interleukin-2 for treatment of HIV reduces hepatitis C viral load in coinfected patients.

Uberti-Foppa C, De Bona A, Morsica G, Guffanti M, Gianotti N, Boeri E, Lazzarin A. Uberti-Foppa C, et al. Among authors: guffanti m. AIDS. 1999 Jan 14;13(1):140-1. AIDS. 1999. PMID: 10207560 No abstract available.

5

Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.

Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, Brambilla A, Vicenzi E, Carrera P, Racca S, Soldini L, Gianotti N, Murone M, Veglia F, Poli G, Lazzarin A. Tambussi G, et al. Among authors: guffanti m. J Infect Dis. 2001 May 15;183(10):1476-84. doi: 10.1086/320188. Epub 2001 Apr 13. J Infect Dis. 2001. PMID: 11319683 Clinical Trial.

6

Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.

Guffanti M, De Pascalis CR, Seminari E, Fusetti G, Gianotti N, Bassetti D, Galli A, Castagna A, Lazzarin A. Guffanti M, et al. AIDS. 2003 Dec 5;17(18):2669-71. doi: 10.1097/00002030-200312050-00017. AIDS. 2003. PMID: 14685066

7

Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.

Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, Rubinacci A. Seminari E, et al. Among authors: guffanti m. HIV Med. 2005 May;6(3):145-50. doi: 10.1111/j.1468-1293.2005.00278.x. HIV Med. 2005. PMID: 15876279 Free article.

8

Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.

Gianotti N, Seminari E, Guffanti M, Boeri E, Villani P, Regazzi M, Bigoloni A, Schira G, Tiberi S, Fusetti G, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: guffanti m. New Microbiol. 2005 Apr;28(2):119-25. New Microbiol. 2005. PMID: 16035256 Clinical Trial.

9

Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.

Seminari E, Guffanti M, Villani P, Gianotti N, Cusato M, Fusetti G, Galli A, Castagna A, Regazzi M, Lazzarin A. Seminari E, et al. Among authors: guffanti m. Eur J Clin Pharmacol. 2005 Aug;61(7):545-9. doi: 10.1007/s00228-005-0966-x. Epub 2005 Jul 23. Eur J Clin Pharmacol. 2005. PMID: 16041598

10

The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients.

Gianotti N, Galli L, Boeri E, De Bona A, Guffanti M, Danise A, Salpietro S, Lazzarin A, Castagna A. Gianotti N, et al. Among authors: guffanti m. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):447-52. doi: 10.1097/01.qai.0000209903.89878.80. J Acquir Immune Defic Syndr. 2006. PMID: 16652052

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page